发明名称 PREDICTION OF RESPONSE TO PLATINUM-BASED THERAPY
摘要 <p>A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.</p>
申请公布号 HK1166371(A1) 申请公布日期 2015.09.11
申请号 HK20120107047 申请日期 2012.07.18
申请人 ATLAS ANTIBODIES AB 发明人 JIRSTRM, KARIN;EBERHARD, JAKOB
分类号 G01N;A61K 主分类号 G01N
代理机构 代理人
主权项
地址
您可能感兴趣的专利